On September 6, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 in Paris, France, September 9 – 13, 2022 (Press release, Iovance Biotherapeutics, SEP 6, 2022, View Source [SID1234619022]). The details of the abstracts, which are available on Iovance.com, are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #844P: Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Presentation Type: Poster
Authors: James Larkin, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4

Abstract #883TiP: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Presentation Type: Trial in Progress (TiP) Poster
Authors: Jason Chesney, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4